
    
      This is a multi-institutional, prospective phase II open-label trial.

      The investigational drug used in this study is pasireotide LAR 60 mg. Pasireotide will be
      administered as an intramuscular injection at the beginning of every cycle which is defined
      as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment
      into the study and continue until disease progression, unacceptable toxicity, or withdrawal
      of consent. Safety and efficacy will be assessed throughout the treatment period.
    
  